Total Payments
$827.27
2024 Payments
$162.99
Companies
27
Transactions
49
Medicare Patients
6,229
Medicare Billing
$863,460
Payment Breakdown by Category
Food & Beverage$805.10 (97.3%)
Education$22.17 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $805.10 | 48 | 97.3% |
| Education | $22.17 | 1 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $199.28 | 12 | $0 (2024) |
| Genentech USA, Inc. | $72.17 | 1 | $0 (2018) |
| Lilly USA, LLC | $40.42 | 3 | $0 (2021) |
| Biogen, Inc. | $38.88 | 3 | $0 (2021) |
| GENZYME CORPORATION | $35.77 | 2 | $0 (2021) |
| PFIZER INC. | $28.69 | 1 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $28.09 | 2 | $0 (2017) |
| AbbVie Inc. | $27.45 | 2 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $26.85 | 3 | $0 (2017) |
| Biohaven Pharmaceuticals, Inc. | $26.52 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162.99 | 10 | Celgene Corporation ($140.82) |
| 2021 | $334.06 | 21 | Celgene Corporation ($39.51) |
| 2020 | $143.39 | 9 | Lilly USA, LLC ($27.53) |
| 2018 | $116.60 | 3 | Genentech USA, Inc. ($72.17) |
| 2017 | $70.23 | 6 | Supernus Pharmaceuticals, Inc. ($28.09) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $8.36 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.66 | General |
| Category: Neuroscience | ||||||
| 09/19/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.32 | General |
| Category: Neuroscience | ||||||
| 08/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $25.52 | General |
| Category: Neuroscience | ||||||
| 06/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.53 | General |
| Category: Neuroscience | ||||||
| 06/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $4.13 | General |
| Category: Neuroscience | ||||||
| 06/10/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Education | In-kind items and services | $22.17 | General |
| Category: Immunology | ||||||
| 05/08/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.11 | General |
| Category: Neuroscience | ||||||
| 05/02/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $5.24 | General |
| Category: Neuroscience | ||||||
| 04/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.95 | General |
| Category: Neuroscience | ||||||
| 12/22/2021 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Neurology | ||||||
| 12/15/2021 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Immune | ||||||
| 12/01/2021 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: NEUROLOGY | ||||||
| 11/03/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: PRIMARY CARE | ||||||
| 10/27/2021 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: NEUROSCIENCE | ||||||
| 09/30/2021 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: Neuroscience | ||||||
| 09/22/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: NEUROSCIENCE | ||||||
| 09/02/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/23/2021 | UPSHER-SMITH LABORATORIES LLC | TOSYMRA (Drug), ZEMBRACE SYMTOUCH | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: NEUROLOGY | ||||||
| 06/16/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: PRIMARY CARE | ||||||
| 06/09/2021 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Neurology | ||||||
| 06/02/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.72 | General |
| Category: Neuroscience | ||||||
| 05/19/2021 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 05/12/2021 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $16.14 | General |
| 05/05/2021 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Food and Beverage | In-kind items and services | $11.42 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,582 | 2,989 | $383,572 | $217,942 |
| 2022 | 11 | 1,519 | 2,898 | $374,327 | $212,016 |
| 2021 | 11 | 1,510 | 2,846 | $364,180 | $212,067 |
| 2020 | 10 | 1,618 | 2,944 | $347,978 | $221,436 |
Total Patients
6,229
Total Services
11,677
Medicare Billing
$863,460
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 400 | 1,476 | $122,178 | $85,421 | 69.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 362 | 377 | $85,670 | $47,045 | 54.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 194 | 288 | $52,445 | $23,879 | 45.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 174 | $20,598 | $15,192 | 73.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 89 | $23,227 | $10,515 | 45.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 242 | 253 | $25,300 | $10,291 | 40.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 102 | 103 | $20,900 | $9,265 | 44.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 88 | 114 | $13,130 | $6,195 | 47.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $12,080 | $5,727 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $5,720 | $2,681 | 46.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 50 | $2,324 | $1,731 | 74.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 329 | 1,393 | $116,569 | $73,845 | 63.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 365 | 373 | $84,430 | $53,077 | 62.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 236 | 358 | $64,990 | $30,005 | 46.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 67 | 201 | $23,784 | $15,318 | 64.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 239 | 248 | $24,800 | $10,606 | 42.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 72 | 75 | $19,529 | $8,991 | 46.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 73 | 96 | $11,060 | $5,557 | 50.2% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 45 | 45 | $9,910 | $5,495 | 55.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $8,360 | $3,553 | 42.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $6,710 | $3,165 | 47.2% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 33 | 49 | $4,185 | $2,402 | 57.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 351 | 1,363 | $113,967 | $73,623 | 64.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 365 | 376 | $86,320 | $55,168 | 63.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 256 | 413 | $73,745 | $35,736 | 48.5% |
About Dr. David Suber, MD
Dr. David Suber, MD is a Neurology healthcare provider based in Tempe, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1477546323.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Suber, MD has received a total of $827.27 in payments from pharmaceutical and medical device companies, with $162.99 received in 2024. These payments were reported across 49 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($805.10).
As a Medicare-enrolled provider, Suber has provided services to 6,229 Medicare beneficiaries, totaling 11,677 services with total Medicare billing of $863,460. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Tempe, AZ
- Active Since 08/25/2005
- Last Updated 02/23/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1477546323
Products in Payments
- ZEPOSIA (Drug) $216.69
- OCREVUS (Biological) $72.17
- UBRELVY (Drug) $53.95
- EMGALITY (Drug) $40.42
- AUBAGIO (Drug) $35.77
- PANZYGA (Biological) $28.69
- TROKENDI XR (Drug) $28.09
- APTIOM (Drug) $26.85
- NURTEC ODT (Drug) $26.52
- BRIUMVI (Drug) $22.17
- Glatiramer Acetate (Drug) $21.44
- BAFIERTAM (Drug) $17.40
- KEVEYIS (Drug) $15.94
- Briviact (Drug) $15.45
- Gamunex-C (Biological) $15.29
- KESIMPTA (Drug) $15.19
- TOSYMRA (Drug) $14.37
- AUSTEDO (Drug) $13.99
- BRILINTA (Drug) $13.93
- VUMERITY (Drug) $11.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.